Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer

Syndax Pharmaceuticals (Nasdaq: SNDX) appointed Aaron A. Ondrey as Chief Financial Officer, effective November 9, 2026, succeeding Keith A. Goldan.

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) appointed Aaron A. Ondrey as Chief Financial Officer, effective November 9, 2026, succeeding Keith A. Goldan.

Goldan is retiring from the CFO position and will remain with the company through the end of 2026 to support the transition. Ondrey brings more than 25 years of financial and operational leadership experience across biotechnology.

Most recently, Ondrey was CFO of Beren Therapeutics, overseeing finance, investor relations and manufacturing operations. Previously, he was CFO of Rocket Pharmaceuticals and CFO and Senior Vice President at Mirati Therapeutics. At Mirati, he supported KRAZATI commercialization and played a role in its acquisition by Bristol Myers Squibb in January 2024. His earlier leadership roles included positions at Arena Pharmaceuticals, Alexion Pharmaceuticals and Regeneron Pharmaceuticals.

Key Figures

CFO appointment effective date: November 9, 2026 Transition support period: Through year-end 2026

CFO appointment effective date

November 9, 2026

Aaron A. Ondrey's appointment

Transition support period

Through year-end 2026

Keith A. Goldan remains with the company

Key Terms

menin inhibitor, monoclonal antibody, colony stimulating factor 1 (csf-1) receptor

3 terms

menin inhibitor medical

"Revuforj® (revumenib), an FDA-approved menin inhibitor"

A menin inhibitor is a type of experimental drug that blocks the action of a protein called menin, which some cancers use to keep growing. Think of it as flipping off a switch that cancer cells rely on to survive; by doing so, these drugs can slow or stop tumor growth. Investors watch menin inhibitors because clinical trial results, regulatory approvals, and market demand determine whether they become valuable cancer treatments and potential revenue drivers.

monoclonal antibody medical

"an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

colony stimulating factor 1 (csf-1) receptor medical

"blocks the colony stimulating factor 1 (CSF-1) receptor"

A cell-surface receptor tyrosine kinase that binds the growth factors colony-stimulating factor 1 (CSF‑1) and interleukin‑34 (IL‑34) to control the survival, proliferation, differentiation and movement of mononuclear phagocytes (macrophages, monocytes and microglia). Ligand binding causes receptor dimerization and autophosphorylation, triggering intracellular signaling pathways that regulate those immune-cell functions; expression is largely restricted to cells of the macrophage/monocyte lineage, which is why modulating this receptor alters numbers or activity of those cells.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

- Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition -

NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Aaron A. Ondrey as Chief Financial Officer, effective November 9, 2026. Mr. Ondrey brings to Syndax more than 25 years of financial and operational leadership experience across the biotechnology industry, with deep expertise in financial management, corporate strategy, commercialization, and mergers and acquisitions.

Current Chief Financial Officer Keith A. Goldan has decided to retire from the position and will remain with the Company through the end of 2026 to support the transition. Mr. Goldan led Syndax’s financial and capital strategy during an important period in the Company’s history. He played a key role in the successful launches of Revuforj and Niktimvo and in initiatives that strengthened the Company's pipeline and innovative R&D platform.

"On behalf of the Board and our entire team, I thank Keith for his many valuable contributions and wish him all the best in his well-earned retirement,” said Michael A. Metzger, Chief Executive Officer of Syndax. “Keith was integral to Syndax's transition into a commercial-stage company and the delivery of three FDA approvals, and he helped lay the foundation for our long-term success."

Mr. Metzger continued, “We are delighted to welcome Aaron to Syndax. He brings decades of experience guiding biopharma companies through commercial expansion and major milestones. The Board and I are confident he will successfully lead our financial strategy and organization as we scale our commercial business, advance our deep pipeline and deliver long-term shareholder value.”

"I am thrilled to join Syndax at such a pivotal moment in the Company's evolution," said Aaron A. Ondrey. "Syndax has built an impressive commercial platform with two approved medicines and a compelling pipeline targeting significant market opportunities. I look forward to partnering with Michael and the broader Syndax team to build on the Company’s leadership position and its strong financial foundation.”

"It has been a privilege to serve as CFO at Syndax and partner with Michael and a highly talented and dedicated team," said Keith A. Goldan, Chief Financial Officer of Syndax. "I am proud of everything we have accomplished together and the positive impact this work continues to have for patients. I am confident Syndax is well positioned for continued success long into the future."

Mr. Ondrey brings extensive leadership and financial experience across both pre-commercial and commercial-stage biopharmaceutical companies. Most recently, he served as Chief Financial Officer of Beren Therapeutics, where he oversaw finance, investor relations, and manufacturing operations. Prior to joining Beren Therapeutics, Mr. Ondrey served as Chief Financial Officer of Rocket Pharmaceuticals, where he led the company’s financial strategy as it prepared for its transition to a commercial-stage organization. Before Rocket Pharmaceuticals, he was Chief Financial Officer and Senior Vice President at Mirati Therapeutics, where he supported the commercialization of KRAZATI® and played a key role in the company’s acquisition by Bristol Myers Squibb in January 2024. Earlier in his career, Mr. Ondrey held senior leadership positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals, building extensive experience in corporate finance, strategic planning, commercialization, and operational execution.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax's product candidates, the acceptance of Syndax and its partners' products in the marketplace, sales, marketing, manufacturing and distribution requirements, and the potential use of its product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes to Revuforj's or Niktimvo’s commercial availability; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax's collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is Syndax's new CFO, and when does he start?

Aaron A. Ondrey becomes Syndax's Chief Financial Officer effective November 9, 2026. He succeeds Keith A. Goldan, who is retiring from the position and will remain with the company through the end of 2026 to support the transition.